Driehaus Capital Management Portfolio holdings
Driehaus Capital Management is a growth equity manager founded in 1982 by Richard Driehaus, an American investor often called the father of momentum investing. Its stock funds look for companies whose earnings growth is picking up, on the view that markets tend to misprice shares after such a turn. Richard Driehaus later founded Driehaus Mutual Funds in 1996. The firm is majority-owned by Driehaus Capital Holdings, which belongs to entities related to its late founder, and its clients include pension plans, endowments, foundations, family offices and the Driehaus mutual funds.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cadence Design Systems
CDNS
|
+$103M |
| 2 |
Credo Technology Group
CRDO
|
+$102M |
| 3 |
Vicor
VICR
|
+$83.8M |
| 4 |
Cipher Digital
CIFR
|
+$74.9M |
| 5 |
Ceco Environmental
CECO
|
+$72.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fabrinet
FN
|
+$240M |
| 2 |
Lumentum
LITE
|
+$130M |
| 3 |
Bloom Energy
BE
|
+$118M |
| 4 |
TSMC
TSM
|
+$114M |
| 5 |
Coherent
COHR
|
+$90.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 27.73% |
| 2 | Technology | 23.9% |
| 3 | Industrials | 20.73% |
| 4 | Financials | 9.01% |
| 5 | Consumer Discretionary | 6.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
TSMC
TSM
$2.06T
| $470M | 2.72% |
984,500
-280,390
| -22% | -$114M |
2013 Q2
52 quarters
|
|
2
Definium Therapeutics
DFTX
$4.77B
| $322M | 1.87% |
6,845,276
+933,387
| +16% | +$23.1M |
2024 Q1
9 quarters
|
|
3
Praxis Precision Medicines
PRAX
$9.29B
| $321M | 1.86% |
959,048
+9,823
| +1% | +$3.11M |
2024 Q1
9 quarters
|
|
4
Xenon Pharmaceuticals
XENE
$3.92B
| $267M | 1.55% |
4,418,557
-73,096
| -2% | -$4.06M |
2020 Q1
25 quarters
|
|
5
Silicon Motion
SIMO
$5.97B
| $262M | 1.52% |
786,074
+276,099
| +54% | +$64M |
2025 Q2
4 quarters
|
|
6
Spyre Therapeutics
SYRE
$10.2B
| $249M | 1.44% |
2,799,166
+8,381
| +0.3% | +$612K |
2023 Q2
12 quarters
|
|
7
DELISTED
Crinetics Pharmaceuticals
CRNX
| $242M | 1.4% |
6,463,551
+67,629
| +1% | +$2.51M |
2020 Q2
24 quarters
|
|
8
DELISTED
Apogee Therapeutics
APGE
| $231M | 1.34% |
1,740,101
-180,699
| -9% | -$16.3M |
2023 Q3
11 quarters
|
|
9
Guardant Health
GH
$21.6B
| $230M | 1.33% |
1,533,985
+9,703
| +0.6% | +$1.06M |
2025 Q1
5 quarters
|
|
10
Planet Labs
PL
$5.22B
| $223M | 1.29% |
6,721,154
-1,197,539
| -15% | -$44.3M |
2025 Q2
4 quarters
|
|
11
Credicorp
BAP
$28.2B
| $217M | 1.26% |
557,228
+106,498
| +24% | +$36.4M |
2024 Q1
9 quarters
|
|
12
Edgewise Therapeutics
EWTX
$5.11B
| $192M | 1.11% |
4,728,623
+250,681
| +6% | +$8.64M |
2023 Q4
10 quarters
|
|
|
13
Vicor
VICR
$7.66B
| $189M | 1.09% |
496,507
+307,044
| +162% | +$83.8M |
2026 Q1
1 quarter
|
|
14
Ultra Clean Holdings
UCTT
$2.26B
| $187M | 1.08% |
1,309,202
+246,826
| +23% | +$21.7M |
2025 Q3
3 quarters
|
|
15
Curtiss-Wright
CW
$17.7B
| $174M | 1.01% |
229,123
+3,364
| +1% | +$2.47M |
2022 Q1
17 quarters
|
|
16
Xometry
XMTR
$6.96B
| $171M | 0.99% |
1,768,213
+255,358
| +17% | +$18.2M |
2024 Q4
6 quarters
|
|
17
TeraWulf
WULF
$6.26B
| $152M | 0.88% |
6,163,879
+100,879
| +2% | +$2.32M |
2025 Q2
4 quarters
|
|
18
Septerna Inc
SEPN
$2.28B
| $148M | 0.86% |
4,433,058
+37,486
| +0.9% | +$1.06M |
2024 Q4
6 quarters
|
|
19
Nextpower Inc. Common Stock
NXT
$15.5B
| $144M | 0.83% |
1,207,194
+169,643
| +16% | +$20.9M |
2025 Q1
5 quarters
|
|
|
20
Ceco Environmental
CECO
$3.04B
| $142M | 0.82% |
1,560,486
+920,594
| +144% | +$72.8M |
2023 Q4
10 quarters
|
|
|
21
Credo Technology Group
CRDO
$25.8B
| $141M | 0.81% |
+517,062
| New | +$102M |
2026 Q2
0 quarters
|
|
22
Carpenter Technology
CRS
$15.2B
| $140M | 0.81% |
227,203
-88,254
| -28% | -$41.6M |
2024 Q3
7 quarters
|
|
23
ICICI Bank
IBN
$125B
| $140M | 0.81% |
4,826,120
+569,260
| +13% | +$15.4M |
2016 Q4
38 quarters
|
|
24
nLIGHT
LASR
$2.58B
| $138M | 0.8% |
1,986,119
+213,422
| +12% | +$14.9M |
2025 Q4
2 quarters
|
|
25
Onto Innovation
ONTO
$10B
| $134M | 0.78% |
354,650
+34,116
| +11% | +$9.7M |
2025 Q3
3 quarters
|
|
Similar funds
Driehaus Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, Driehaus Capital Management held 439 positions worth $17.3B, up 27% from $13.6B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Driehaus Capital Management's Q2 2026 filing shows 84 new, 139 increased, 108 reduced and 85 closed positions. Its largest new stake was Cadence Design Systems: 293,693 shares worth $110M. The largest sale was Fabrinet, an estimated $240M.
By sector, the portfolio is most concentrated in Healthcare at 28% of assets, up from 27% a quarter earlier, followed by Technology and Industrials.
- Driehaus Capital Management's largest Q2 2026 buy was Cadence Design Systems: 293,693 shares worth $110M.
- Driehaus Capital Management added most to Vicor in Q2 2026, an estimated $83.8M increase.
- Driehaus Capital Management's biggest Q2 2026 reduction was Fabrinet, cutting an estimated $240M.
- Driehaus Capital Management fully exited National Vision in Q2 2026, selling an estimated $89.9M.
- Driehaus Capital Management's ten largest holdings make up 16% of its $17.3B portfolio in Q2 2026.
- Driehaus Capital Management opened 84 new positions and closed 85 in Q2 2026.
- Driehaus Capital Management's portfolio value rose 27% quarter-over-quarter to $17.3B.
Based on Driehaus Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.